Trandolapril
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Trandolapril: From ACE Inhibitor Therapy to Malignant Renovascular Hypertension
One-Sentence Summary
Trandolapril is an ACE inhibitor (ACEi); detailed original-indication and mechanism-of-action records were not available in this evidence pack, though ACEi-class drugs are typically used for hypertension and heart failure via RAAS blockade. The TxGNN model’s top-scoring prediction for this drug is Malignant Renovascular Hypertension (score 99.92%), but this candidate currently has zero supporting clinical trials or literature, and the evidence pack’s own mechanistic notes flag it as a likely contraindicated, high-risk scenario rather than a genuine repurposing opportunity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (drug is annotated as an ACE inhibitor; ACEi class is typically indicated for hypertension/heart failure) |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 (no clinical trials, no literature) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for trandolapril was not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on the classification referenced in the evidence pack’s own rationale annotations, trandolapril is an ACE inhibitor: it blocks the renin-angiotensin-aldosterone system (RAAS) by inhibiting conversion of angiotensin I to angiotensin II, lowering blood pressure and reducing renal vascular resistance.
On the surface, this mechanism looks applicable to renovascular hypertension, since RAAS activation is central to that condition’s pathophysiology. However, malignant renovascular hypertension is frequently associated with bilateral (or solitary-kidney) renal artery stenosis. In this specific setting, ACE inhibitors carry a well-recognised risk of precipitating acute renal failure, because glomerular filtration in stenotic kidneys becomes dependent on angiotensin II-mediated efferent arteriolar constriction — which ACEi therapy removes. The evidence pack’s own rationale explicitly identifies this as “a clinical contraindication or high-risk scenario rather than a priority repurposing direction,” which is consistent with the complete absence of clinical trials or literature for this drug-disease pair.
In short, the high TxGNN similarity score appears to reflect embedding-space proximity between hypertension-related disease terms rather than a genuine, clinically actionable repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
No SAHPRA registrations were found for trandolapril in this evidence pack (market status: Not Marketed, 0 licenses on record).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: the evidence pack’s mechanistic rationale specifically flags that ACE inhibitors are associated with a risk of acute renal failure in patients with bilateral renal artery stenosis — a condition commonly underlying malignant renovascular hypertension. This should be treated as a critical safety signal for this specific candidate pending confirmation against the official PI (TFDA/SAHPRA warning data is currently missing — DG001, Blocking).
Conclusion and Next Steps
Decision: Hold
Rationale: The highest-scoring TxGNN prediction for trandolapril (malignant renovascular hypertension) has no clinical trial or literature support (Evidence Level L5, decision stage S0), and the drug’s own mechanistic profile suggests a probable contraindication (ACEi-induced acute renal failure risk in stenotic renal vasculature) rather than therapeutic benefit. This candidate should not advance without dedicated safety and mechanistic review.
To proceed, the following is needed:
- SAHPRA/TFDA-approved Professional Information, particularly warnings/contraindications related to renal artery stenosis (DG001, Blocking)
- Confirmed mechanism-of-action data from DrugBank (DG002, High)
- Independent clinical or preclinical evidence specific to malignant renovascular hypertension, since none currently exists
- For context: among the six TxGNN-predicted indications provided for this drug, only chronic pulmonary heart disease (rank 6) has any literature support (one preclinical rat study, PMID 8989645) and reached decision stage S1 (“Research Question”); this may be a more worthwhile direction to monitor going forward, though it remains preclinical-only (L4) and unconfirmed in humans.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.